North America is the world’s largest market for atopic dermatitis drugs and holds about half of total global market volume. Increased prevalence of atopic dermatitis and food/skin allergies are expected to be the major reasons for the growth of atopic dermatitis drugs market. The CAGR of the North American market is expected to be 4.17% for the forecast period of 2019-2027.

NORTH AMERICA ATOPIC DERMATITIS DRUGS MARKET FORECAST 2019-2027

North America Atopic Dermatitis Drugs Market by Route of Administration (Roa) (Topical, Oral, Injectable) by Drug Class (Topical Antibiotics, Topical Antihistamines, Topical Corticosteroids, Topical Moisturizers/emollients, Topical Calcineurin Inhibitors, Immunomodulators, Off-label Therapies, Systemic Agents, Pde-4 Inhibitor, Interleukin Inhibitor) by Geography.

Request free sample

Report Summary

The U.S. is the largest contributor towards the success of North America’s atopic dermatitis drugs market. Yet, there are large unmet needs in the treatment of individuals with eczema or atopic dermatitis in the region. The annual burden of atopic dermatitis in terms of economics is roughly estimated at $ xx million, a figure which includes direct costs such as medical visits and medications and also indirect costs like loss of productivity of patients and caregivers. Out of all the various drug classes, topical corticosteroids are the ones that are most widely used hence, generating the highest revenue. Another option which people have turning to in recent times is off-label therapies. The market for off-label therapies is also expected to grow by 2027.

The leading players in the North American atopic dermatitis drugs market Leo Pharma, Allergan Plc, Bayer Ag, Bristol-Myers Squibb, Pfizer, Sanofi Sa, Encore Dermatology, Astellas Pharma Inc., Meda Pharmaceuticals (Mylan N.V.), Valent Pharmaceutical Inc., Novartis Ag, Aqua Pharmaceuticals (An Almirall Company), Biofrontera Ag, Stiefel Laboratories, Inc, Galderma Sa, Regeneron Pharmaceuticals .

To request a free sample copy of this report, please complete the form below:

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

RESEARCH SCOPE
- STUDY GOALS
- SCOPE OF THE MARKET STUDY
- WHO WILL FIND THIS REPORT USEFUL?
- STUDY AND FORECASTING YEARS
RESEARCH METHODOLOGY
- SOURCES OF DATA
  - SECONDARY DATA
  - PRIMARY DATA
- TOP-DOWN APPROACH
- BOTTOM-UP APPROACH
- DATA TRIANGULATION
EXECUTIVE SUMMARY
- MARKET SUMMARY
- KEY FINDINGS
  - TOPICAL ROUTE OF ADMINISTRATION HOLDS MAJORITY OF THE OVERALL MARKET SHARE
  - INTERLEUKIN INHIBITOR MARKET IS ANTICIPATED TO GENERATE HIGHEST REVENUE

MARKET DETERMINANTS
- MARKET DRIVERS
  - GROWING PREVALENCE OF FOOD ALLERGIES EXACERBATING ATOPIC DERMATITIS
  - GROWING FOCUS ON SYSTEMATIC THERAPIES
  - INCREASING USE OF PHARMACOLOGICAL PRODUCTS IN DEVELOPING COUNTRIES
- MARKET RESTRAINTS
  - STRINGENT REGULATIONS FOR PRODUCT APPROVAL
  - GENERIC COMPETITION
- MARKET OPPORTUNITIES
  - INCREASING M&A LEADING TO MARKET CONSOLIDATION
  - LAUNCH OF FIRST BIOLOGIC FOR ATOPIC DERMATITIS
  - GROWING FOCUS ON NOVEL DRUGS
- MARKET CHALLENGES
  - BLACK BOX WARNING FOR ELIDEL AND PROTOPIC
  - HIGHLY GENERICIZED MARKET
  - POOR PATIENT ADHERENCE DUE TO INADEQUATE INFORMATION ON DRUG USAGE

MARKET SEGMENTATION
- MARKET BY ROUTE OF ADMINISTRATION (ROA) 2019-2027
  - TOPICAL
  - ORAL
  - INJECTIBLES
- MARKET BY DRUG CLASS 2019-2027
  - TOPICAL ANTIBIOTICS
  - TOPICAL ANTIHISTAMINES
  - TOPICAL CORTICOSTEROIDS
  - TOPICAL MOISTURIZERS/EMOLLIENTS
  - TOPICAL CALCINEURIN INHIBITORS
  - IMMUNOMODULATORS
  - OFF-LABEL THERAPIES
  - SYSTEMIC AGENTS
  - PDE4 INHIBITOR
  - INTERLEUKIN INHIBITOR

KEY ANALYTICS
- PORTER’S FIVE FORCES ANALYSIS
  - THREAT OF NEW ENTRANTS
  - THREAT OF SUBSTITUTE
  - BARGAINING POWER OF SUPPLIERS
  - BARGAINING POWER OF BUYERS
  - THREAT OF COMPETITIVE RIVALRY
- OPPORTUNITY MATRIX
- PIPELINE ANALYSIS
- LEGAL, POLICY AND REGULATORY ISSUES
GEOGRAPHICAL ANALYSIS
- NORTH AMERICA
  - THE UNITED STATES
  - CANADA

COMPANY PROFILES
- ALLERGAN PLC
  - COMPANY OVERVIEW
  - PRODUCT PORTFOLIO
  - SWOT ANALYSIS
  - STRATEGIC INITIATIVES
- AQUA PHARMACEUTICALS (AN ALMIRALL COMPANY)
  - COMPANY OVERVIEW
  - PRODUCT PORTFOLIO
  - SWOT ANALYSIS
- ASTELLAS PHARMA INC.
  - COMPANY OVERVIEW
  - PRODUCT PORTFOLIO
  - SWOT ANALYSIS
  - STRATEGIC INITIATIVES
- BAYER AG
  - COMPANY OVERVIEW
  - PRODUCT PORTFOLIO
  - SWOT ANALYSIS
  - STRATEGIC INITIATIVES
- BIOFRONTERA AG
  - COMPANY OVERVIEW
  - PRODUCT PORTFOLIO
  - SWOT ANALYSIS
- BRISTOL-MYERS SQUIBB
  - COMPANY OVERVIEW
  - PRODUCT PORTFOLIO
  - SWOT ANALYSIS
- STIEFEL LABORATORIES, INC
  - COMPANY OVERVIEW
  - PRODUCT PORTFOLIO
  - SWOT ANALYSIS
- ENCORE DERMATOLOGY
  - COMPANY OVERVIEW
  - PRODUCT PORTFOLIO
  - SWOT ANALYSIS
  - STRATEGIC INITIATIVES
- GALDERMA SA
  - COMPANY OVERVIEW
  - PRODUCT PORTFOLIO
  - SWOT ANALYSIS
  - STRATEGIC INITIATIVES
- LEO PHARMA
  - COMPANY OVERVIEW
  - PRODUCT PORTFOLIO
  - SWOT ANALYSIS
  - STRATEGIC INITIATIVES
- MEDA PHARMACEUTICALS (MYLAN N.V.)
  - COMPANY OVERVIEW
  - PRODUCT PORTFOLIO
  - SWOT ANALYSIS
  - STRATEGIC INITIATIVES
- NOVARTIS AG
  - COMPANY OVERVIEW
  - PRODUCT PORTFOLIO
  - SWOT ANALYSIS
  - STRATEGIC INITIATIVES
- PFIZER
  - COMPANY OVERVIEW
  - PRODUCT PORTFOLIO
  - SWOT ANALYSIS
  - STRATEGIC INITIATIVES
- REGENERON PHARMACEUTICALS
  - COMPANY OVERVIEW
  - PRODUCT PORTFOLIO
  - SWOT ANALYSIS
  - STRATEGIC INITIATIVES
- SANOFI SA
  - COMPANY OVERVIEW
  - PRODUCT PORTFOLIO
  - SWOT ANALYSIS
  - STRATEGIC INITIATIVES
- VALENT PHARMACEUTICAL INC.
  - COMPANY OVERVIEW
  - PRODUCT PORTFOLIO
  - SWOT ANALYSIS

TABLE LIST

TABLE 1 NORTH AMERICA ATOPIC DERMATITIS DRUGS MARKET 2019-2027 ($ MILLION)

TABLE 2 RECENT MERGERS AND ACQUISITIONS IN ATOPIC DERMATITIS DRUGS MARKET

TABLE 3 NORTH AMERICA ATOPIC DERMATITIS DRUGS MARKET BY ROA 2019-2027 ($ MILLION)

TABLE 4 NORTH AMERICA ATOPIC DERMATITIS DRUGS MARKET IN TOPICAL ROA 2019-2027 ($ MILLION)

TABLE 5 NORTH AMERICA ATOPIC DERMATITIS DRUGS MARKET IN ORAL ROA 2019-2027 ($ MILLION)

TABLE 6 NORTH AMERICA ATOPIC DERMATITIS DRUGS MARKET IN INJECTIBLES ROA 2019-2027 ($ MILLION)

TABLE 7 NORTH AMERICA ATOPIC DERMATITIS DRUGS MARKET BY DRUG CLASS 2019-2027 ($ MILLION)

TABLE 8 NORTH AMERICA ATOPIC DERMATITIS DRUGS MARKET IN TOPICAL ANTIBIOTICS 2019-2027 ($ MILLION)

TABLE 9 NORTH AMERICA ATOPIC DERMATITIS DRUGS MARKET IN TOPICAL ANTIHISTAMINES 2019-2027 ($ MILLION)

TABLE 10 NORTH AMERICA ATOPIC DERMATITIS DRUGS MARKET IN TOPICAL CORTICOSTEROIDS 2019-2027 ($ MILLION)

TABLE 11 NORTH AMERICA ATOPIC DERMATITIS DRUGS MARKET IN TOPICAL MOISTURIZERS/EMOLLIENTS 2019-2027 ($ MILLION)

TABLE 12 NORTH AMERICA ATOPIC DERMATITIS DRUGS MARKET IN TOPICAL CALCINEURIN INHIBITORS 2019-2027 ($ MILLION)

TABLE 13 NORTH AMERICA ATOPIC DERMATITIS DRUGS MARKET IN IMMUNOMODULATORS 2019-2027 ($ MILLION)

TABLE 14 NORTH AMERICA ATOPIC DERMATITIS DRUGS MARKET IN OFF-LABEL THERAPIES 2019-2027 ($ MILLION)

TABLE 15 NORTH AMERICA ATOPIC DERMATITIS DRUGS MARKET IN SYSTEMIC AGENTS 2019-2027 ($ MILLION)

TABLE 16 NORTH AMERICA ATOPIC DERMATITIS DRUGS MARKET IN PDE4 INHIBITOR 2019-2027 ($ MILLION)

TABLE 17 NORTH AMERICA ATOPIC DERMATITIS DRUGS MARKET IN INTERLEUKIN INHIBITOR 2019-2027 ($ MILLION)

TABLE 18 PIPELINE PORTFOLIO OF DIABETES DRUGS MARKET

TABLE 19 REGULATORY FRAMEWORK IN ATOPIC DERMATITIS MARKET

TABLE 20 NORTH AMERICA ATOPIC DERMATITIS DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE LIST

FIGURE 1 NORTH AMERICA ATOPIC DERMATITIS DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE 2 THE UNITED STATES ATOPIC DERMATITIS DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE 3 CANADA ATOPIC DERMATITIS DRUGS MARKET 2019-2027 ($ MILLION)

Segmentation

GEOGRAPHICAL ANALYSIS
- NORTH AMERICA
  - THE UNITED STATES
  - CANADA

MARKET SEGMENTATION
- MARKET BY ROUTE OF ADMINISTRATION (ROA) 2019-2027
  - TOPICAL
  - ORAL
  - INJECTIBLES
- MARKET BY DRUG CLASS 2019-2027
  - TOPICAL ANTIBIOTICS
  - TOPICAL ANTIHISTAMINES
  - TOPICAL CORTICOSTEROIDS
  - TOPICAL MOISTURIZERS/EMOLLIENTS
  - TOPICAL CALCINEURIN INHIBITORS
  - IMMUNOMODULATORS
  - OFF-LABEL THERAPIES
  - SYSTEMIC AGENTS
  - PDE4 INHIBITOR
  - INTERLEUKIN INHIBITOR